Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Inclusion Criteria

• •Provision of written informed consent prior to any study related procedures
• •Inoperable, Gastro-Entero-Pancreatic-Neuroendocrine Tumour G1 or G2 (Proliferation Index, Ki67-Index: 0 to ≤20%) confirmed by pathological/histological assessment
• •Progressive disease within 12 months before inclusion (RECIST 1.1: increase of \>20% tumour load; by Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)
• •Measurable disease according to RECIST 1.1.
• •Metastatic disease confirmed by CT/MRI.
• •Functioning or non-functioning NET (G1, G2).
• •Positive Octreo-Scan (≥ Grade 2 Krenning scale) or positive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-TATE (Tyr3-Thre8-Octreotide or DOTA-Tyr3-octreotate)/TOC (Tyr3-octreotide) -PET (Positron-Emission-Tomography) -CT within 12 months prior to screening